WHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia
|
|
|
- Samantha Sims
- 5 years ago
- Views:
Transcription
1 Blood Malignancies-II Prof. Dr. Herman Hariman, a Ph.D, SpPK (KH). Prof. Dr. Adikoesoema Aman, SpPK (KH) Dept. of Clinical Pathology, School of Medicine, University of North Sumatra
2 WHO classification for Lymphoid Disoders Is quite complicated
3 WHO Classification B-cell neoplasms T- and NK-cell neoplasms Precursor B-cell neoplasm Precursor T-cell neoplasm Precursor B-lymphoblastic leukemia/lymphoma (precursor B-cell acute lymphoblastic leukemia) Precursor T-lymphoblastic lymphoma/leukemia (precursor T- cell acute lymphoblastic leukemia) Mature (peripheral) B-cell neoplasms Mature (peripheral) T-cell neoplasms B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma T-cell prolymphocytic leukemia T-cell granular lymphocytic leukemia B-cell prolymphocytic leukemia Aggressive NK-cell leukemia Lymphoplasmacytic lymphoma Adult T-cell lymphoma/leukemia Splenic marginal zone B-cell lymphoma (with or w/o villous lymphocytes) (human T-cell lymphotropic virus type I positive) Extranodal NK/T-cell lymphoma, nasal type Hairy cell leukemia Enteropathy type T-cell lymphoma Plasma cell myeloma/plasmacytoma Hepatosplenic gammadelta T-cell lymphoma Extranodal marginal zone B-cell lymphoma of mucosa- associated lymphoid tissue type Subcutaneous panniculitis-like T-cell lymphoma Mycosis fungoides/sezary syndrome Nodal marginal zone B-cell lymphoma (with or w/o monocytoid B cells) Anaplastic large cell lymphoma, T/null-cell, primary cutaneous type Follicular lymphoma Peripheral T-cell lymphoma, not otherwise Mantle cell lymphoma Diffuse large B-cell lymphoma characterized Angioimmunoblastic T-cell lymphoma Mediastinal large B-cell lymphoma Anaplastic large cell lymphoma, T/null-cell, Primary effusion lymphoma primary systemic type Burkitt's lymphoma/burkitt's cell leukemia
4 Lymphoproliferative Disorders Precursor B and T cell acute Lymphoblastic Leukaemia Mature peripheral p e B cell tumour Mature aueperipheral ea T Cell tumour Hodgkin s Lymphoma
5 A.L.L-L1 usually 75% call, 25% B-ALL
6 A.L.L-L2 usually T-ALL
7 A.L.L-L3 Burkitt s stype ALL
8 Mature (peripheral) B cell tumour Chronic Lymphocytic Leukaemia Atypical CLL Mantle Cell Lymphoma B-Prolymphocytic Leukaemia Marginal Zone Lymphoma Large Cell Transformation of CLL Follicular Lymphoma Non-endemic Burkitt's Lymphoma Diffuse Large B-cell Lymphoma Myeloma, Plasmacytoma and MGUS Hairy Cell Leukaemia
9 CLL
10 CLL BIOPSY
11 Atypical CLL
12 Mature (peripheral) B cell tumour Chronic Lymphocytic Leukaemia Atypical CLL Mantle Cell Lymphoma B-Prolymphocytic Leukaemia Marginal Zone Lymphoma Large Cell Transformation of CLL Follicular Lymphoma Non-endemic Burkitt's Lymphoma Diffuse Large B-cell Lymphoma Myeloma, Plasmacytoma and MGUS Hairy Cell Leukaemia
13 Multiple Myeloma More than 15% plasma cells in the bone marrow. Monoclonal immunoglobulin peak on SPEP more than 3 gm/dl. Presence of Bence Jones protein in urine. Decreased levels of normal immunoglobulins.
14
15 Diagnosis i of Multiple Myeloma Cell surface markers: CD38, plasma cell antigen, and cell surface immunoglobulins. Monoclonality can be demonstrated by immunoperoxidase staining with kappa and lambda antibodies.
16 Diagnosis and Staging Workup Bone marrow biopsy and aspirate Serum protein electrophoresis and immunofixation Skeletal survey Plain x-rays are better than bone scan. Lytic lesions do not show up well on bone scan. Quantitative immunoglobulins
17 Serum Protein Electrophoresis Alb. α 1 α 2 γ Total protein 7.2 α 2 globulin 0.5 albumin 4.5 β globulins li 0.7 α 1 globulin 0.15 γ globulin 1.4 β Normal Spike Alb. α 1 α 2 β γ Total protein 7.9 α 2 globulin 0.6 albumin 3.9 β globulins li 0.7 α 1 globulin 0.19 γ globulin 2.4 Monoclonal
18 Monoclonal Immunoglobulin Spike on Serum Protein Electrophoresis (SPEP) Multiple myeloma Non-Hodgkin s lymphoma Monoclonal gammopathy of undetermined significance (MGUS). N t li i ll i ifi t l t Not clinically significant unless present in high quantity (over 3 gm/dl).
19 Durie-Salmon Staging System Stage I mass for Multiple Myeloma Hemoglobin > 10 g/dl Low myeloma cell Normal bone, or solitary plasmacytoma Low immunoglobulin spike (Mcomponent) IgG < 5 g/dl, IgA < 3 g/dl Bence-Jones protein < 4 g/24h
20 Durie-Salmon Staging System Stage II mass for Multiple Myeloma Intermediate myeloma cell In between Stages I and III Subclassification A: Normal renal function - serum creatinine level < 2.0 mg/dl B: Abnormal renal function - serum creatinine level ³ 2.0 mg/dl
21 Durie-Salmon Staging System Stage III mass for Multiple Myeloma Hemoglobin < 8.5 g/dl Serum calcium > 12 mg/dl High myeloma cell Multiple lytic bone lesions on x-ray High M-component IgG > 7 g/dl, IgA > 5 g/dl Bence-Jones protein > 12 g/24h
22 Hodgkin s and Non-Hodgkin s Lymphoma The most important diagnostic tools in Malignant Lymphoma is the HISTOPATHOLOGY (TISSUE BIOPSY)
23 Hodgkin s and Non-Hodgkin s Lymphoma All patients having been suspected to have Malignant Lymphoma must undergo BMP for both aspiration and biopsy to show the staging (Ann Arbor) Multiple puncture must be done When (+)ve; it is stage IV
24
25 Mantle cel lnhl A high power view reveals some heterogeneity of the lymphoid cells. Large immunoblast like cells are noted with the more mature appearing lymphs.
26 B-Prolymphocytic Leukaemia
27 Monotonous population of marginal zone lymphocytes with abundant cytoplasm Monotonous population of marginal zone lymphocytes with abundant cytoplasm form indistinct margin with larger germinal center cells having larger vesicular (clear) nuclei.
28 Follicular NHL
29 Burkitt NHL
30 DLBCL
31 MM >15% PC
32 MM
33 Hairy Cell Leukaemia
34 Mature (peripheral) T-cell Tumours T-Prolymphocytic Leukaemia Large Granular Lymphocytosis Mycosis Fungoides / Sezary Syndrome Lymphomatoid papulosis and CD30 + cutaneous anaplastic lymphoma Adult T-cell Leukaemia/Lymphoma Nodal T-cell Lymphomas
35 T-Prolymphocytic Leukaemia
36 Large Granular Lymphocytosis
37 MYCOSIS FUNGOIDES
38 Sezary cells may have an irregular nuclear border. Nucleoli are generally not present.
39 Adult T cell leukemialymphoma Peripheral blood smear showing abnormal lymphocytes with nuclear indentation or lobulation (Wright's stain).htlv1 Japanese and Carribean
40 HODGKIN LYMPHOMA
41 HODGKIN LYMPHOMA, LYMPHOCYTE-RICH, HRC CELLS
42 HD mixed cellularity Eo, Plasma, Lympho
43 HD Mixed Cellularity, Eos stained, lymph and plasma
44 HD Lymphocyte Depleted
45 HD Nodular Sclerosing
46 THANK YOU
Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital
Lymphoma/CLL 101: Know your Subtype Dr. David Macdonald Hematologist, The Ottawa Hospital Function of the Lymph System Lymph Node Lymphocytes B-cells develop in the bone marrow and influence the immune
Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.
Non-Hodgkin Lymphoma Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract. Protocol revision date: January 2005 No AJCC/UICC staging system Procedures Cytology
Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
Classifications of lymphomas
Classifications of lymphomas Lukes and Collins Kiel classification Working formulation REAL classification (1994) WHO classification (2000) WHO CLASSIFICATIONF OF NEOPLASMS HAEMATOPETIC AND LYMPHOID TISSUES
2010 Hematopoietic and Lymphoid ICD-O Codes - Alphabetical List THIS TABLE REPLACES ALL ICD-O-3 Codes
Acute basophilic leukemia 9870/3 Acute biphenotypic leukemia [OBS] 9805/3 Acute erythroid leukemia 9840/3 Acute megakaryoblastic leukemia 9910/3 Acute monoblastic and monocytic leukemia 9891/3 Acute myeloid
2012 Hematopoietic and Lymphoid ICD-O Codes - Numerical List THIS TABLE REPLACES ALL ICD-O-3 Codes
Malignant lymphoma, NOS 9590/3 Non-Hodgkin lymphoma, NOS 9591/3 B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma 9596/3 Primary
Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307
Clinical Policy: (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that
Lymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham
Lymphoid Neoplasms Sylvie Freeman Department of Clinical Immunology, University of Birmingham Incidence of Haematological Malignancies UK2001 (CRUK) Malignancy New Cases All Cancers 271,000 Leukaemia 6,760
Large cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
Combinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation
Major subgroups according to the World Health Organisation (WHO) Classification Myeloproliferative neoplasms (MPN) Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or
During past decades, because of the lack of knowledge
Staging and Classification of Lymphoma Ping Lu, MD In 2004, new cases of non-hodgkin s in the United States were estimated at 54,370, representing 4% of all cancers and resulting 4% of all cancer deaths,
88-year-old Female with Lymphadenopathy. Faizi Ali, MD
88-year-old Female with Lymphadenopathy Faizi Ali, MD Clinical History A 88-year-old caucasian female presented to our hospital with the complaints of nausea, vomiting,diarrhea, shortness of breath and
Hepatic Lymphoma Diagnosis An Algorithmic Approach
Hepatic Lymphoma Diagnosis An Algorithmic Approach Ryan M. Gill, M.D., Ph.D. University of California, San Francisco PLEASE TURN OFF YOUR CELL PHONES Disclosure of Relevant Financial Relationships USCAP
Integrated Hematopathology. Morphology and FCI with IHC
Integrated Hematopathology Morphology and FCI with IHC FrontMatter.indd i 9/6/2009 9:30:12 PM FrontMatter.indd ii 9/6/2009 9:30:18 PM Integrated Hematopathology Morphology and FCI with IHC Cherie H Dunphy,
Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: CP.PHAR.307
Clinical Policy: (Bendeka, Treanda) Reference Number: CP.PHAR.307 Effective Date: 02/17 Last Review Date: 02/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
Plasma cell myeloma (multiple myeloma)
Plasma cell myeloma (multiple myeloma) Common lymphoid neoplasm, present at old age (70 years average) Remember: plasma cells are terminally differentiated B-lymphocytes that produces antibodies. B-cells
LYMPHOMAS an overview of some subtypes of NHLs
One of the confusing aspects of the lymphoid neoplasms concerns the use of the descriptive terms "leukemia" and "lymphoma." LYMPHOMAS an overview of some subtypes of NHLs Leukemia is used for lymphoid
Burkitt lymphoma. Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8
Heme 8 Burkitt lymphoma Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8 Most common is t(8;14) Believed to be the fastest growing tumor in humans!!!! Morphology
Change Summary - Form 2018 (R3) 1 of 12
Summary - Form 2018 (R3) 1 of 12 Form Question Number (r3) Type Description New Text Previous Text Today's date was removed 2018 N/A Today's Date Removed from Key Fields 2018 N/A HCT Type 2018 N/A Product
From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport
From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology Songlin Zhang, MD, PhD LSUHSC-Shreveport I have no Conflict of Interest. FNA on Lymphoproliferative
Small B-cell (Histologically Low Grade) Lymphoma
Frequency of Lymphoid Neoplasms Small B-cell (Histologically Low Grade) Lymphoma Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital B-cell neoplasms 88% Diffuse large B-cell lymphoma
Contents. vii. Preface... Acknowledgments... v xiii
Contents Preface... Acknowledgments... v xiii SECTION I 1. Introduction... 3 Knowledge-Based Diagnosis... 4 Systematic Examination of the Lymph Node... 7 Cell Type Identification... 9 Cell Size and Cellularity...
Non-Hodgkin s Lymphomas Version
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Use of Immunophenotyping/ Genetic Testing in Differential Diagnosis of Mature B-Cell
3.1 Introduction. It is emphasised that not all tests are necessarily required in every case. 3.2 Taxonomic structure
CHAPTER 3 CLASSIFICATION 3.1 Introduction Accurate diagnosis underpins lymphoma management. Historically, competing lymphoma classifications have been a source of frustration to pathologists, clinicians
Lymphatic system component
Introduction Lymphatic system component Statistics Overview Lymphoma Non Hodgkin s Lymphoma Non- Hodgkin's is a type of cancer that originates in the lymphatic system. It is estimated to be the sixth most
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma
Case 3. Ann T. Moriarty,MD
Case 3 Ann T. Moriarty,MD Case 3 59 year old male with asymptomatic cervical lymphadenopathy. These images are from a fine needle biopsy of a left cervical lymph node. Image 1 Papanicolaou Stained smear,100x.
Lymphoma: The Basics. Dr. Douglas Stewart
Lymphoma: The Basics Dr. Douglas Stewart Objectives What is lymphoma? How common is it? Why does it occur? How do you diagnose it? How do you manage it? How do you follow patients after treatment? What
DETERMINATION OF A LYMPHOID PROCESS
Chapter 2 Applications of Touch Preparation Cytology to Intraoperative Consultations: Lymph Nodes and Extranodal Tissues for Evaluation of Hematolymphoid Disorders INTRODUCTION As discussed in Chap. 1,
LYMPHOID MALIGNANCIES & NEW IDEAS
LYMPHOID MALIGNANCIES & NEW IDEAS LEUKEMIAS AND LYMPHOMAS. Malignancies of B, T, or NK cells are lymphoid; of any other hematopoietic cells, myeloid. We ll only discuss lymphoid malignancies here, and
7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour
7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic
Immunopathology of Lymphoma
Immunopathology of Lymphoma Noraidah Masir MBBCh, M.Med (Pathology), D.Phil. Department of Pathology Faculty of Medicine Universiti Kebangsaan Malaysia Lymphoma classification has been challenging to pathologists.
Common Problem Areas. WHO Classification. Defines separate diseases (entities) with their CLINICAL AGGRESSIVENESS LOW GRADE / HIGH GRADE
WHO Classification Defines separate diseases (entities) with their CLINICAL AGGRESSIVENESS REVIEW OF MOST COMMON LYMPHOMA ENTITIES Dr Stefan Dojcinov LOW GRADE / HIGH GRADE (June 2014) The Non-Hodgkin
A.C. Feller. J. Diebold Histopathology of Nodal and Extranodal Non-Hodgkin's Lymphomas
A.C. Feller. J. Diebold Histopathology of Nodal and Extranodal Non-Hodgkin's Lymphomas Springer Berlin Heidelberg New York Hong Kong London Milan Paris Tokyo Alfred C. Feller Jacques Diebold in Collaboration
Michi Shinohara MD Associate Professor University of Washington/Seattle Cancer Care Alliance Dermatology, Dermatopathology
Michi Shinohara MD Associate Professor University of Washington/Seattle Cancer Care Alliance Dermatology, Dermatopathology Agenda Overview of cutaneous T and B- cell lymphomas Diagnosis, Staging, Prognosis
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes Lauren R. Teras, PhD 1 ; Carol E. DeSantis, MPH 2 ; James R. Cerhan, MD, PhD 3 ; Lindsay M. Morton, PhD 4 ; Ahmedin Jemal, DVM,
Osteosclerotic Myeloma (POEMS Syndrome)
Osteosclerotic Myeloma (POEMS Syndrome) Osteosclerotic Myeloma (POEMS Syndrome) Synonyms Crow-Fukase syndrome Multicentric Castleman disease Takatsuki syndrome Acronym coined by Bardwick POEMS Scheinker,
The primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam:
Hematology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified hematologist
LYMPHOID MALIGNANCIES & NEW IDEAS
LYMPHOID MALIGNANCIES & NEW IDEAS LEUKEMIAS AND LYMPHOMAS. Malignancies of B, T, or NK cells are lymphoid; of any other hematopoietic cells, myeloid. We ll only discuss lymphoid malignancies here, and
Harmesh Naik, MD. GME Presentation to Family Practice Residents October 16, 2013.
Harmesh Naik, MD. GME Presentation to Family Practice Residents October 16, 2013. Lymphoma: Lympho-proliferative disorders arising from lymphocytes Heterogeneous group of disorders Differing patterns of
Pathology #07. Hussein Al-Sa di. Dr. Sohaib Al-Khatib. Mature B-Cell Neoplasm. 0 P a g e
Pathology #07 Mature B-Cell Neoplasm Hussein Al-Sa di Dr. Sohaib Al-Khatib 0 P a g e Thursday 18/2/2016 Our lecture today (with the next 2 lectures) will be about lymphoid tumors This is a little bit long
HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD. Parts 2 and 3
HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD Parts 2 and 3 NEOPLASTIC LYMPHOID DISEASES Introduction o The bone marrow is the source of all cells in the
Contractor Name: Novitas Solutions, Inc. Contractor Number: Contractor Type: MAC A. LCD ID Number: L35032 Status: A-Approved
LCD for Flow Cytometry (L35032) Contractor Name: Novitas Solutions, Inc. Contractor Number: 12501 Contractor Type: MAC A LCD ID Number: L35032 Status: A-Approved Contractor Information LCD Information
5000 International Clinical Cytometry Society: Practical Flow Cytometry in Hematopathology A Case-Based Approach
5000 International Clinical Cytometry Society: Practical Flow Cytometry in Hematopathology A Case-Based Approach Joseph A DiGiuseppe, MD, PhD Hartford Hospital Disclosures In the past 12 months, I have
癌症診療準則與核心測量 - 淋巴瘤 彰化基督教醫院內科部血液腫瘤科張正雄. Agenda
癌症診療準則與核心測量 - 淋巴瘤 彰化基督教醫院內科部血液腫瘤科張正雄 Agenda Lymphocyte differentiation Classification of lymphomas Disease definitions and symptoms Tests that identify specific lymphoid histologies Staging Cancer registry
Overview of Cutaneous Lymphomas: Diagnosis and Staging. Lauren C. Pinter-Brown MD, FACP Health Sciences Professor of Medicine and Dermatology
Overview of Cutaneous Lymphomas: Diagnosis and Staging Lauren C. Pinter-Brown MD, FACP Health Sciences Professor of Medicine and Dermatology Definition of Lymphoma A cancer or malignancy that comes from
Cutaneous Lymphoid Proliferations: A Comprehensive Textbook of Lymphocytic Infiltrates of the Skin
Cutaneous Lymphoid Proliferations: A Comprehensive Textbook of Lymphocytic Infiltrates of the Skin Magro, Cynthia M., MD ISBN-13: 9780471695981 Table of Contents Chapter One: Introduction to the Classification
Recent diagnostic and therapeutic innovations of T-cell-lymphoma. Prof. Nossrat Firusian, Recklinghausen, Germany
Recent diagnostic and therapeutic innovations of T-cell-lymphoma Prof. Nossrat Firusian, Recklinghausen, Germany NODAL Angioimmunoblastic T-cell Lymphoma Peripheral T-cell-Lymphoma Anaplastic Large-cell-Lymphoma
Hematology Case Conference 8/5/03
Hematology Case Conference 8/5/03 Bone Marrow Case Patient: Emmxxx Lylexxx 74 year old AA female S/P craniotomy for SDH. Pt has Hx of HTN, DM, Crohn s disease, (R) nephrectomy. Bone marrow for abnormal
Hematopathology Lab. Third year medical students
Hematopathology Lab Third year medical students Objectives Identify the lesion Know the specific name of the lesion Know associated disease Know relevant pathologic background Spherocytes: appear small,
Leukemia And Lymphoma In The Nervous System
Leukemia And Lymphoma In The Nervous System If you are searching for the book Leukemia and Lymphoma in the Nervous System in pdf format, then you've come to the right site. We presented complete variant
MANAGEMENT OF LYMPHOMAS
MANAGEMENT OF LYMPHOMAS Challenges & Recommendations F. Chite Asirwa, MD. Internal Medicine Physician Medical Oncologist & Hematologist Director-AMPATH Oncology & Hematology @Kenya Physicians Association
Case #1. Robert J. Glinert, M.D. David C. Fisher, M.D. Dana Farber Cancer Institute
Case #1 Robert J. Glinert, M.D. David C. Fisher, M.D. Dana Farber Cancer Institute Patient History Part I 76 year-old man 1997 diagnosed with MGUS (biclonal) during evaluation of (self-limited) anemia.
Immunohistochemical classification of haematolymphoid tumours. Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital
Immunohistochemical classification of haematolymphoid tumours Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital Malignant lymphoproliferative diseases What are they? Haematolymphoid
Introduction: The Revised (4 th Edition) World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues
Society for Hematopathology Scientific Symposium USCAP Companion Meeting, Boston, MA March 8, 2009 Boston, MA Steven H. Swerdlow and James Vardiman, Moderators Introduction: The Revised (4 th Edition)
Lymphoma and Myeloma Kris3ne Kra4s, M.D.
Lymphoma and Myeloma Kris3ne Kra4s, M.D. Hematologic Malignancies Leukemia Malignancy of hematopoie3c cells Starts in bone marrow, can spread to blood, nodes Myeloid or lymphoid Acute or chronic Lymphoma
Pearls and pitfalls in interpretation of lymphoid lesions in needle biopsies
Pearls and pitfalls in interpretation of lymphoid lesions in needle biopsies Megan S. Lim MD PhD University of Pennsylvania October 8, 2018 Objectives To understand how the trend toward less invasive lymph
Patterns of Lymphoid Neoplasia in Peripheral Blood. Leon F. Baltrucki, M.D. Leon F. Baltrucki, M.D. Disclosure
Patterns of Lymphoid Neoplasia in Peripheral Blood Leon F. Baltrucki, M.D. Leon F. Baltrucki, M.D. Disclosure Dr Baltrucki has received an honorarium for his participation as a faculty presenter in this
Corrigenda. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run
Corrigenda WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run In addition to corrections of minor typographical errors, corrections
Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
Classification of Hematologic Malignancies. Patricia Aoun MD MPH
Classification of Hematologic Malignancies Patricia Aoun MD MPH Objectives Know the basic principles of the current classification system for hematopoietic and lymphoid malignancies Understand the differences
Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
The spectrum of flow cytometry of the bone marrow
The spectrum of flow cytometry of the bone marrow Anna Porwit Lund University Faculty of Medicine Dept. of Clinical Sciences Div. Oncology and Pathology anna.porwit@med.lu.se Disclosure of speaker s interests
THE SOCIETY FOR Hematopathology and the European
SPECIAL ARTICLE World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting Airlie House, Virginia, November
Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital
Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic
T CELL LYMPHOMA ANALYSIS
T CELL LYMPHOMA ANALYSIS Charles Goolsby, Ph.D. Floyd E. Patterson Research Professor of Pathology Northwestern Feinberg School of Medicine c-goolsby@northwestern.edu 1 T CELL LYMPHOMA ANALYSIS Diverse
Staging Non-Hodgkin Lymphoma
Staging Non-Hodgkin Lymphoma James O. Armitage, MD Dr. Armitage is Professor, Department of Internal Medicine, Joe ABSTRACT Non-Hodgkin Lymphomas are always treatable and frequently curable malignancies.
Lymphoid Neoplasms Associated With IgM Paraprotein A Study of 382 Patients
Hematopathology / LYMPHOMAS WITH IGM PARAPROTEIN Lymphoid Neoplasms Associated With IgM Paraprotein A Study of 382 Patients Pei Lin, MD, 1 Suyang Hao, MD, 1* Beverly C. Handy, MD, 2 Carlos E. Bueso-Ramos,
UNIVERSITÀ DI PISA FACOLTÀ DI MEDICINA E CHIRURGIA TESI DI LAUREA
UNIVERSITÀ DI PISA FACOLTÀ DI MEDICINA E CHIRURGIA Corso di Laurea Specialistica in Medicina e Chirurgia TESI DI LAUREA How to treat Splenic Marginal Zone Lymphoma (SMZL) in patients unfit for surgery
C r h ist s op o h p e h r e R. R F l F ow o er e s, s M D, D M S
1 Christopher R. Flowers, MD, MS Associate Professor of Hematology and Medical Oncology Winship Cancer Institute Emory University School of Medicine Atlanta, Georgia 2 1 Anyone can get blood cancer One
Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.
Non-Hodgkin Lymphoma Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract. Protocol revision date: January 2005 No AJCC/UICC staging system Procedures Cytology
Molecular Pathology of Lymphoma (Part 1) Rex K.H. Au-Yeung Department of Pathology, HKU
Molecular Pathology of Lymphoma (Part 1) Rex K.H. Au-Yeung Department of Pathology, HKU Lecture outline Time 10:00 11:00 11:15 12:10 12:20 13:15 Content Introduction to lymphoma Review of lymphocyte biology
The patient had a mild splenomegaly but no obvious lymph node enlargement. The consensus phenotype obtained from part one of the exercise was:
Case History An 86 year old male was admitted to hospital with chest infection. Haematological examination subsequently revealed the following: Hb- 11.0 g/dl; WBC- 67.1 x 10^9/l; PLT- 99 x10^9/l; RBC-
Tel: Fax: Received: 25, Jul, 2014 Accepted: 16, Dec, 2014
IJHOSCR International Journal of Hematology- Oncology and Stem Cell Research Original Article T-cell/Natural killer-cell neoplasms presenting as leukemia- Case series from single tertiary care center Shano
Anaemias and other Pesky Haematology Questions
Anaemias and other Pesky Haematology Questions 3 main topics How do I work out an anaemia.. That oh too common paraprotein patient. Those mildly raised lymphocyte count GP discussed patient with me over
Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.
Non-Hodgkin Lymphoma Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract. Protocol revision date: January 2004 No AJCC/UICC staging system Procedures Cytology
Lymphoma Tumor Board Quiz! Laboratory Hematology: Basic Cell Morphology
Lymphoma Tumor Board Quiz! Laboratory Hematology: Basic Cell Morphology CABOT RINGS Cabot rings in a patient with hemolytic anemia. Cabot ring (red arrow) and Howell-Jolly body (blue arrow). Observed in
Hematology 101. Rachid Baz, M.D. 5/16/2014
Hematology 101 Rachid Baz, M.D. 5/16/2014 Florida 101 Epidemiology Estimated prevalence 8,000 individuals in U.S (compare with 80,000 MM patients) Annual age adjusted incidence 3-8/million-year 1 More
Reviewing the ICD-10 classification of haematological neoplasms on its way to ICD-11
WHO-FIC NETWORK MEETING Tokyo, Japan haematological neoplasms on its way to ICD-11 Ulrich Vogel, Robert Jakob, Michael Schopen, Harald Stein, Stefan Krause Abstract: haematological neoplasms on its way
HEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint
HEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Hematology MOC exam blueprint Based on feedback from physicians that MOC assessments should
1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes on the next page
COME HOME Non-Hodgkin pathway development worksheet, v6 September 2014 1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes
Hematopoietic Stem-Cell & Clinical Coverage Policy No: 11A-11 Bone Marrow Transplantation Amended Date: March 1, 2017 For Non-Hodgkin s Lymphoma
Hematopoietic Stem-Cell & Clinical Coverage Policy No: 11A-11 Bone Marrow Transplantation Amended Date: March 1, 2017 For Non-Hodgkin s Lymphoma Table of Contents 1.0 Description of the Procedure, Product,
The College of American Pathologists offers these protocols
Strategies for Laboratory and Patient Management Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms of the Bone Marrow A Basis for Checklists LoAnn C. Peterson, MD; Steven
SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT MYELOMA CHAPTER 11C REVISED: SEPTEMBER 2016
MYELOMA Quantitative Markers-Myeloma Assessment Quantitative markers are biochemicals that are recorded in tests on body fluids such as serum and urine. Applicable Disease Sites The myeloma disease site
Case Report Primary Hairy Cell Leukemia/Lymphoma of the Breast: A Case Report and Review of the Literature
Hindawi Publishing Corporation Volume 2014, Article ID 497027, 5 pages http://dx.doi.org/10.1155/2014/497027 Case Report Primary Hairy Cell Leukemia/Lymphoma of the Breast: A Case Report and Review of
Forms Revision: Myeloma Changes
Sharing knowledge. Sharing hope. Forms Revision: Myeloma Changes J. Brunner, PA-C and A. Dispenzieri, MD February 2013 Disclosures Janet Brunner, PA-C I have no relevant conflicts of interest to disclose.
Canine T-cell Lymphomas: A Morphological, Immunological, and Clinical Study of 46 New Cases
Vet Pathol 39:92 19 (22) Canine T-cell Lymphomas: A Morphological, Immunological, and Clinical Study of 46 New Cases C. FOURNEL-FLEURY, F. PONCE, P. FELMAN, A. BLAVIER, C. BONNEFONT, L. CHABANNE, T. MARCHAL,
SH/EAHP Workshop 2011 Los Angeles, California, USA
SH/EAHP Workshop 2011 Los Angeles, California, USA October 27-29, 2011 Session 3 Non-Mycosis Fungoides CTCL Patty Jansen & Rein Willemze Introduction Submitted: 101 cases + 7 cases group 1: 108 Deactivated
JMSCR Vol. 03 Issue 06 Page June 2015
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x An Indolent Natural Killer Cell Leukemia Presenting with Bilateral Ankle Arthritis and Low Grade Fever Abstract Author Subhash Chandra
Approach to Core Biopsy Specimens
BDIAP 108th Symposium on Haematopathology Joint Meeting of the BDIAP and BLPG at-bristol, Anchor Road, Harbourside, Bristol BS1 5DB 15th - 17th May 2014 Approach to Core Biopsy Specimens Dr Stefan Dojcinov
BACKGROUND INFORMATION ON NON-HODGKIN S LYMPHOMA
BACKGROUND INFORMATION ON NON-HODGKIN S LYMPHOMA General Non-Hodgkin s lymphomas (NHLs) encompass several unique malignant lymphoid disease entities that vary in clinical behavior, morphologic appearance,
Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas. Original Policy Date
MP 7.03.13 Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013
Flow cytometric analysis of B-cell lymphoproliferative disorders
Flow cytometric analysis of B-cell lymphoproliferative disorders David M. Dorfman, M.D., Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard Medical School Boston, MA Objectives Review
Bortezomib (Velcade)
Bortezomib (Velcade) Policy Number: Original Effective Date: MM.04.003 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription Drugs Place(s)
Retroperitoneal lymphoma mixed cell type icd 10
Retroperitoneal lymphoma mixed cell type icd 10 The Borg System is 100 % Retroperitoneal lymphoma mixed cell type icd 10 Lymphoma, non hodgkins, stage 1; Lymphoma, non hodgkins, stage 2; Lymphoma, non
Unknown Case 6. Ann T. Moriarty, MD
Unknown Case 6 Ann T. Moriarty, MD Unknown Case 6 61 year old male with an enlarged cervical lymph node. He has a history of lung carcinoma, renal cell carcinoma and lymphoma. Case 6 Image 1: Fine needle
LEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
EPIDEMIOLOGY AND SPECIFIC RISK FACTORS FOR MALIGNANT LYMPHOMA IN THE SINGAPORE POPULATION
EPIDEMIOLOGY AND SPECIFIC RISK FACTORS FOR MALIGNANT LYMPHOMA IN THE SINGAPORE POPULATION WONG KIN YOKE NATIONAL UNIVERSITY OF SINGAPORE 2012 EPIDEMIOLOGY AND SPECIFIC RISK FACTORS FOR MALIGNANT LYMPHOMA